CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1b Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Subjects With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas or Chronic Lymphocytic Leukemia

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02242045
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:15.870979+00:00
Published At: 2021-03-19T00:00:00+00:00
Record Updated At: 2021-03-19
Results Posted At: 2021-03-19
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Chronic Lymphocytic Leukemia", "Indolent Non-Hodgkin Lymphoma", "Follicular Lymphoma", "Small Lymphocytic Lymphoma", "Lymphoplasmacytic Lymphoma (With or Without Waldenstrom Macroglobulinemia)", "Marginal Zone Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2021-03-19"
protocolSection.identificationModule.nctId: "NCT02242045"
protocolSection.identificationModule.officialTitle: "A Phase 1b Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Subjects With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas or Chronic Lymphocytic Leukemia"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2021-03-19"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.